Cardiol Therapeutics Inc. shares rise 3.24% intraday after BioCardia announces positive trial results for CardiAMP Cell Therapy.

Cardiol Therapeutics Inc. rose 3.24% intraday, with BioCardia, Inc. announcing the pricing of a public offering of an aggregate of 4,800,000 shares of its common stock and short-term warrants to purchase up to 4,800,000 shares of common stock, at a combined public offering price of $1.25 per share and accompanying short-term warrant. The short-term warrants will have an exercise price of $1.25 per share, will be exercisable upon issuance and will expire two years thereafter. The closing of the offering is expected to occur on.